SEARCH:
Signup to create an account
test
Lone Star Opposes SWS Group's Merger Plans

SWS Group Inc. (NYSE: SWS), a diversified financial services holding company, recently announced a merger agreement with Hilltop Holdings Inc. (NYSE: HTH) in a cash and stock transaction amounting to 0.2469 shares of HTH and $1.94 in cash for each share of SWS.

test
JANA Partners Tightens the Leash on PetSmart

PetSmart Inc. (NASDAQ: PETM), a leading retailer of pets and pet-related goods and services, recently hired JPMorgan Chase to analyze the possibility of a leveraged share buyback, according to Reuters reports.


test
HighTech Set To Disrupt the BioTech Industry

In a new world of high tech discoveries, Silicon Valley is creating advances that are now being used to revolutionize the biotech industry.

Recent 8K Filings
ADVANCED ENERGY INDUSTRIES INC
CREDIT SUISSE AG
TWENTYFOUR/SEVEN VENTURES, INC.
GEPCO, LTD.
GRUMA SAB DE CV
ZHONE TECHNOLOGIES INC
GENETIC TECHNOLOGIES LTD
PRANA BIOTECHNOLOGY LTD
RESPONSE GENETICS INC

Recent Insider Filings
CLEARSIGN COMBUSTION CORP (BELL LON E)
CLEARSIGN COMBUSTION CORP (ISAACSON SCOTT P)
AMBARELLA INC (VERHALEN ANDREW W)
CLEARSIGN COMBUSTION CORP (PIRNAT STEPHEN E)
NEPHROGENEX, INC. (TAGLIETTI MARCO)
OPKO HEALTH, INC. (FROST PHILLIP MD ET AL)
AIR T INC (SWENSON NICHOLAS JOHN)
LEXMARK INTERNATIONAL INC /KY/ (COHON JARED L)
LEXMARK INTERNATIONAL INC /KY/ (COLEMAN J EDWARD)



Executive Interview
Quantum Energy, Inc. (OTC: QEGY)
In this episode we speak with Mr. Russell Smith, EVP of Public Affairs for Quantum Energy, about the company's plans to build 21st Century Energy Centers in the Bakken oil fields.


Executive Interview
Theralase Technologies (OTC: TLTFF)
In this episode we will be talking to Mr. Roger Dumoulin-White, President & CEO of Theralase Technologies. Theralase designs, manufactures and markets patented, super-pulsed laser technology used in eliminating pain and destroying cancer.


Executive Interview
Galectin Therapeutics (NASDAQ: GALT)
In this SECFilings.com Executive Interview we speak with Mr. Jim Czirr, Executive Chairman of Galectin Therapeutics.